Application Research of Immunoassay in Clinical Diagnosis of Autoimmune Diseases
Abstract
Methods: A total of 128 patients suspected of having autoimmune diseases who were admitted for anesthesia in a hospital from January
2022 to December 2024 were chosen as the observation group, and 64 healthy patients who underwent physical examination during this
period were selected as the control group. ANA, anti-double-stranded DNA antibody (anti-dsDNA), anti-ENA, rheumatoid factor (RF),
anti anti-cyclic citrullinated peptide antibody (anti-CCP), immunoglobulins, complement C3, and C4 were detected in both groups. The
positivity rates and diagnostic performances were compared. Results: The positive rates of ANA (anti–dsDNA), anti-ENA, RF, and antiCPC in the observation set were all higher than those in the control set (P<0.05). The sensitivity of the combined detection of multiple indicators was 92.19%, and the accuracy was 90.10% compared to single-item detection. Conclusion: Immunoassays can provide laboratory
evidence for screening, classification, and diagnosis of anasthetized disease. This tool can help improve the detection speed and reduce the
risk of missed diagnoses.
Keywords
Full Text:
PDFReferences
[1] Dinse, G. E., Parks, C. G., Weinberg, C. R., Co, C. A., Wilkerson, J., Zeldin, D. C., Miller, F. W., & Satoh, M. (2022). Increasing prevalence of antinuclear antibodies in the United States. Arthritis & Rheumatology, 74(12), 2032–2041.
[2] von Mühlen, C. A., Garcia-De La Torre, I., Infantino, M., Damoiseaux, J., Andrade, L. E. C., Carballo, O. G., Conrad, K., Francescantonio, P. L. C., Fritzler, M. J., Herold, M., Klotz, W., Cruvinel, W. D., Mimori, T., Satoh, M., Musset, L., & Chan, E. K. L. (2021). How to
report the antinuclear antibodies test on HEp-2 cells: Guidelines from the ICAP initiative. Immunologic Research, 69(6), 594–608.
[3] Bizzaro, N., Villalta, D., Bini, V., Migliorini, P., Franceschini, F., Piantoni, S., Garrafa, E., & Tozzoli, R. (2022). Multiparametric autoantibody analysis: A new paradigm for the diagnosis of connective tissue diseases. Arthritis Research & Therapy, 24(1), 278.
[4] Sokolova, M. V., Schett, G., Steffen, U., & Raza, K. (2022). Autoantibodies in rheumatoid arthritis: Historical background and novel
findings. Clinical Reviews in Allergy & Immunology, 63(1), 138–151.
[5] Parker, M., Zheng, Z., Lasarev, M. R., Baer, A. N., Casciola-Rosen, L., & McCoy, S. S. (2024). Novel autoantibodies help diagnose antiSSA antibody negative Sjögren disease and predict abnormal labial salivary gland pathology. Annals of the Rheumatic Diseases, 83(9),
1169–1180.
[6] Cinquanta, L., Bizzaro, N., Villalta, D., Morozzi, G., Tonutti, E., & Bassetti, D. (2021). Standardization and quality assessment under
the perspective of automated computer-assisted HEp-2 immunofluorescence assay systems. Autoimmunity Reviews, 20(3), 102691.
[7] Dinse, G. E., Parks, C. G., Weinberg, C. R., Co, C. A., Wilkerson, J., Zeldin, D. C., Miller, F. W., & Satoh, M. (2020). Increasing prevalence of antinuclear antibodies in the United States. Arthritis & Rheumatology, 72(6), 1026–1035.
[8] Cafaro, G., Bartoloni, E., Bistoni, O., Alunno, A., & Gerli, R. (2023). Autoantibody status according to multiparametric assay accurately
estimates connective tissue disease classification and identifies clinically relevant disease subsets. RMD Open, 9(3), e003365.
DOI: http://dx.doi.org/10.70711/pmr.v3i9.9887
Refbacks
- There are currently no refbacks.
